---
title: "Traws Pharma, Inc. (TRAW.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TRAW.US.md"
symbol: "TRAW.US"
name: "Traws Pharma, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-20T17:04:17.892Z"
locales:
  - [en](https://longbridge.com/en/quote/TRAW.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TRAW.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TRAW.US.md)
---

# Traws Pharma, Inc. (TRAW.US)

## Company Overview

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.trawspharma.com](https://www.trawspharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: D (0.63)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 157 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1103.96% |  |
| Net Profit YoY | 59.81% |  |
| P/B Ratio | -3.04 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 16150038.63 |  |
| Revenue | 2733000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -4037.74% | E |
| Profit Margin | -710.83% | E |
| Gross Margin | 0.00% | E |
| Revenue YoY | 1103.96% | A |
| Net Profit YoY | 59.81% | B |
| Total Assets YoY | -57.22% | E |
| Net Assets YoY | -188.52% | E |
| Cash Flow Margin | 110.17% | C |
| OCF YoY | 1103.96% | A |
| Turnover | 0.20 | D |
| Gearing Ratio | 165.12% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Traws Pharma, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "1103.96%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "59.81%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-3.04",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "16150038.63",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2733000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-4037.74%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-710.83%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "1103.96%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "59.81%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-57.22%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-188.52%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "110.17%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "1103.96%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.20",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "165.12%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.16 | 110/189 | 2.54 | 2.20 | 1.72 |
| PB | -3.04 | 215/189 | 3.41 | 2.18 | 1.43 |
| PS (TTM) | 5.91 | 104/189 | 34.81 | 5.67 | 4.44 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-20T04:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.65 |
| Highest Target | 8.00 |
| Lowest Target | 3.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/TRAW.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/TRAW.US/norm.md)
- [Related News](https://longbridge.com/en/quote/TRAW.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/TRAW.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**